Viewing nowAcyta 50 mg Tablet (Sitagliptin Hydrochloride Monohydrate)
Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Ahn-Guk Pharmaceutical Co., Ltd.

MFDS item code 202004052 · Approved 2020.05.29 · Insurance code 650205700
Improvement of glycemic control in type 2 diabetes mellitus
This medication helps patients with type 2 diabetes to manage their blood sugar levels more effectively alongside dietary and exercise therapy. Initially, it can be used alone, and if blood sugar control is difficult even without a history of taking diabetes medications, it may be combined with metformin. Additionally, it is used together when blood sugar control is insufficient with monotherapy of sulfonylureas, metformin, thiazolidinediones, or insulin. Furthermore, it can enhance efficacy when added to different regimens in cases where blood sugar is not well-controlled.
Administer 100 mg once daily as monotherapy or combination therapy; the maximum daily dose is 100 mg. This medicine may be taken with or without food. When this medicine is administered in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of sulfonylurea- or insulin-induced hypoglycemia (see Precautions for Use, 5. General Precautions). Patients with renal impairment Assessment of renal function before starting treatment with this medicine and periodically thereafter is recommended, as dosage adjustment is required according to renal function. 1. No dosage adjustment is required in patients with mild renal impairment (eGFR ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dosage adjustment is required in patients with moderate renal impairment (eGFR ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily to patients with moderate renal impairment (eGFR ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily to patients with severe renal impairment (eGFR ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (eGFR < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.
This medication can rarely cause serious allergic reactions, so if symptoms such as skin rash, difficulty breathing, or swelling of the face or neck appear within three months of administration, discontinue use immediately and consult a healthcare provider. While taking this medication, symptoms of acute pancreatitis may occur, so if abdominal pain, nausea, or vomiting develops, inform a doctor immediately. This medication should not be used in patients with type 1 diabetes or diabetic ketoacidosis, and it should not be administered to those with known allergic reactions to this drug or its ingredients. Patients with impaired kidney function may require dosage adjustments, so it is important to conduct kidney function tests before administration and check kidney status regularly. Mild respiratory infections, headaches, nasopharyngitis, diarrhea, nausea, and other side effects may occur during this treatment. Particularly, when taken alongside other hypoglycemic agents such as insulin or sulfonylureas, the risk of hypoglycemia is increased, so patients should be alert to the symptoms of hypoglycemia and adjust doses of other medications if necessary. Rare side effects such as severe arthralgia or skin blistering have also been reported, so inform healthcare professionals immediately if experiencing joint pain or skin abnormalities. Pregnant or breastfeeding women are not recommended to take this medication, and safety in children or adolescents under 18 has not been established. Due to potential kidney function decline, elderly patients should be evaluated for kidney function and dosage adjustments are necessary before using this medication. In cases of overdose, general supportive measures should be taken, and if needed, some drugs may be removed via dialysis. There are generally few drug interactions, but those taking digoxin should be monitored closely.
Severe allergic reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, nasopharyngitis, upper respiratory infection, headache, diarrhea, abdominal pain, nausea, constipation, vomiting, arthralgia accompanied by severe and disability, vesicular pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute renal failure, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, indigestion, dizziness, increased serum triglycerides, gastritis, severe hypoglycemia, weight loss, hypertension, hypernatremia, erectile dysfunction
Not everyone experiences these, and they can vary from person to person.
Store this medication in a tightly closed container to prevent air infiltration and keep it at room temperature between 1°C and 30°C. This will help maintain the medication’s effectiveness for longer.
Pale yellow-pink, round, biconvex film-coated tablet
30 tablets/box [10 tablets/PTP X 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowSitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Ahn-Guk Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Korea United Pharm., Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 128.5mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.

Sitagliptin Hydrochloride Hydrate 28.35mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 56.7mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.

Sitagliptin Hydrochloride Hydrate 113.4mg
Tablet · Prescription medication
Daewoong Bio Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.